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Mapping the geographical distribution of yaws
In 2012, after the publication of a randomised 
controlled trial showing that a single oral dose of 
azithromycin was as eﬀ ective as intramuscular 
benzathine benzylpenicillin for the treatment of yaws,1 
WHO launched a new, ambitious initiative—the Morges 
strategy—for the eradication of the disease by 2020.2 
The strategy is to give one round of total community 
treatment with azithromycin to endemic communities, 
followed by regular surveys to identify and treat new 
cases and their contacts.2 Yaws fulﬁ ls the Dahlem 
workshop criteria for a potentially eradicable disease,3 
since there is an eﬀ ective single-dose treatment and a 
simple, aﬀ ordable serological test to conﬁ rm diagnosis, 
although the possibility of a non-human reservoir 
has not been entirely excluded.4 However, the ﬁ rst 
step in the yaws eradication programme is to map 
its global epidemiology. In The Lancet Global Health, 
Oriol Mitja and colleagues5 synthesise all the available 
data from published prevalence surveys, cases reported 
to WHO by  national programmes and, when these 
data were not available, from cases reported to them 
by national programme managers. They ﬁ nd that, 
during 2010–13, 215 308 (84%) of 256 343 cases of 
yaws were concentrated in just three countries—Papua 
New Guinea, Solomon Islands, and Ghana—and that 
transmission occurred in focal rural communities in a 
further eight.
As the authors admit, the major limitation of this 
study is the weakness of routinely reported data. 
Although a high percentage of all cases of yaws 
reported to WHO were from Ghana, Papua New Guinea, 
and Solomon Islands, and only 13 countries report 
cases, elimination has only been reported in two of 
the 73 countries in which it was formerly endemic 
(Ecuador and India).6 Yaws has not been regarded as a 
public health priority in most countries since the major 
eradication campaigns of the 1950s, and in many of 
them it is no longer a reportable disease. Therefore, 
under-reporting is probably a major problem. 
National yaws surveillance programmes report 
cases based on clinical diagnosis without serological 
conﬁ rmation, and WHO has distributed an illustrated 
handbook to improve clinical diagnosis. However, even 
in experienced hands, clinical diagnosis is unreliable. 
Studies in Papua New Guinea, Solomon Islands, and 
Ghana have found that Haemophilus ducreyi rather 
than Treponema pallidum was present in the ulcers of 
many children with a clinical diagnosis of yaws,7 and a 
recent study of 90 children with clinical yaws in a rural 
district of Ghana,8 from which yaws cases are reported 
every year, found that none of them had serological 
evidence of T pallidum infection. When diagnosis of 
yaws is based solely on clinical ﬁ ndings, over-reporting 
is likely to be a substantial problem, and certiﬁ cation 
of local elimination will not be possible. Fortunately, 
a new point-of-care serological test that detects 
both treponemal and non-treponemal antibodies 
is both sensitive and speciﬁ c for the diagnosis of yaws.9 
Blinding trachoma, another neglected tropical disease, 
is targeted by WHO for global elimination as a public 
health problem by 2020. As in the case of yaws, until 
recently, no recent information on the prevalence of 
the disease was available in many districts in countries 
believed to have endemic trachoma. A global mapping 
project is underway in which the prevalence of active 
and late-stage trachoma is being measured, using an 
agreed sampling strategy and diagnostic criteria, in 
every district in the world that might harbour cases of 
trachoma.10 This project is expected to be complete 
by the end of 2015, and the results will be used to 
target human and ﬁ nancial resources to districts where 
interventions are needed. This major project is funded 
by a grant of £10·6 million from the UK Department for 
International Development. 
A similar global mapping project for yaws would 
establish the extent and geographical distribution of 
the disease, and enable national programme managers 
to focus interventions on communities where 
transmission continues. Conﬁ rmation of the eradication 
of yaws will be diﬃ  cult without such a mapping exercise 
in formerly endemic districts since, without this, 
unidentiﬁ ed pockets of infections will probably  persist. 
Careful thought will need to be given to the sampling 
strategy and diagnostic criteria to be used, which will 
need to include serological conﬁ rmation of at least 
a proportion of cases. As yet, no serological test can 
distinguish between yaws and syphilis, but most clinical 
cases of yaws are in children younger than 10 years, in 
whom syphilis is unlikely. Funds will be needed for a 
global yaws mapping project but, in the meantime, the 
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possibility of including yaws in prevalence surveys for 
trachoma and other neglected tropical diseases that are 
already funded should be considered. 
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